Skip to main content

CORRECTION article

Front. Immunol., 07 December 2020
Sec. Cancer Immunity and Immunotherapy

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Ru ZhouRu Zhou1Mahboubeh YazdanifarMahboubeh Yazdanifar1Lopamudra Das RoyLopamudra Das Roy1Lynsey M. WhildingLynsey M. Whilding2Artemis GavrillArtemis Gavrill2John MaherJohn Maher2Pinku Mukherjee*Pinku Mukherjee1*
  • 1Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, United States
  • 2School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Hospital Campus, London, United Kingdom

A Corrigendum on
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

by Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J and Mukherjee P (2019). Front. Immunol. 10:1149. doi: 10.3389/fimmu.2019.01149

There was an error in the Funding statement. The correct name for the funder is DOD.

In the original article, we neglected to include the funder DOD, W81XWH-18-1-0711 to Ru Zhou, Mahboubeh Yazdanifar, Lopamudra Das Roy, Lynsey M. Whilding, Artemis Gavrill, John Maher, and Pinku Mukherjee.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: triple-negative breast cancer, immunotherapy, MUC28z CAR T cells, MUC1, TAB004

Citation: Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J and Mukherjee P (2020) Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth. Front. Immunol. 11:628776. doi: 10.3389/fimmu.2020.628776

Received: 12 November 2020; Accepted: 13 November 2020;
Published: 07 December 2020.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2020 Zhou, Yazdanifar, Roy, Whilding, Gavrill, Maher and Mukherjee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Pinku Mukherjee, cG11a2hlcmpAdW5jYy5lZHU=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.